Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2950-4910
  • E-ISSN: 2950-4902

Abstract

Introduction

Reverse-phase high-performance liquid chromatography is a simple, quick, accurate, sensitive, and reproducible technique for quantitatively analyzing Tadalafil and Macitentan in pharmaceutical dosage form. This method is novel as it allows for the simultaneous quantification of both Tadalafil and Macitentan in a single run, which is not widely reported in existing literature.

Methods

Waters Alliance-e2695 was used to perform the chromatographic separation of Tadalafil and Macitentan using an Agilent Eclipse XDB C18 (150 x 4.6 mm, 3.5 µ) column and a mobile phase that contained acetonitrile: 0.1% TFA in a 50:50% v/v ratio. At room temperature, the flow rate was found to be 1.0 ml/min, and a photodiode array detector was used to monitor the absorption at 301 nm.

Results

For Tadalafil and Macitentan, the theoretical plate count was not less than 2000, and the tailing factor should not exceed 2. All measurements have a percentage relative standard deviation of peak areas that is consistently smaller than 2.

Discussion

The suggested approach was validated in compliance with ICH Q2 (R1) regulations. This method was deemed simple, cost-effective, accurate, precise, and reliable for quantitative analysis of the stability study of Tadalafil and Macitentan. The novelty of this work mainly depends on the use of specific mobile phase composition, pH, column type, or detection wavelength that achieves excellent separation and peak resolution within a shorter run time.

Conclusion

This study shows excellent sensitivity with low LOD/LOQ values, and superior efficiency through rapid analysis, good resolution, and robustness, making it suitable for routine quality control and pharmaceutical analysis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/csch/10.2174/0129504910393905250929062420
2025-10-03
2025-12-07

  • From This Site

    /content/journals/csch/10.2174/0129504910393905250929062420
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ForgueS.T. PattersonB.E. BeddingA.W. PayneC.D. PhillipsD.L. WrishkoR.E. MitchellM.I. Tadalafil pharmacokinetics in healthy subjects.Br. J. Clin. Pharmacol.200661328028810.1111/j.1365‑2125.2005.02553.x 16487221
     [Google Scholar]
  2. ArifS.A. PoonH. Tadalafil: A long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.Clin. Ther.2011338993100410.1016/j.clinthera.2011.06.008 21762988
     [Google Scholar]
  3. DalvieD. ObachR.S. KangP. PrakashC. LoiC.M. HurstS. NeddermanA. GouletL. SmithE. BuH.Z. SmithD.A. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.Chem. Res. Toxicol.200922235736810.1021/tx8004357 19146377
     [Google Scholar]
  4. AbdulmuminA. Recent analytical approaches to counterfeit drug detection.J. Appl. Pharm. Sci.20111613
     [Google Scholar]
  5. AbhaG.D. VidhyaB.K. SunilR. Validated HPLC method for simultaneous quantification of tadalafil and dapoxetine HCl in bulk drug and formulation.Int. J. Pharm. Pharm. Sci.20124654658
     [Google Scholar]
  6. ThenappanT. OrmistonM.L. RyanJ.J. ArcherS.L. Pulmonary arterial hypertension: Pathogenesis and clinical management.BMJ2018360j549210.1136/bmj.j5492 29540357
     [Google Scholar]
  7. BedanM. GrimmD. WehlandM. SimonsenU. InfangerM. KrügerM. A focus on macitentan in the treatment of pulmonary arterial hypertension.Basic Clin. Pharmacol. Toxicol.2018123210311310.1111/bcpt.13033 29719121
     [Google Scholar]
  8. SidhartaP.N. TreiberA. DingemanseJ. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.Clin. Pharmacokinet.201554545747110.1007/s40262‑015‑0255‑5 25860376
     [Google Scholar]
  9. AzarmiS. RoaW. LöbenbergR. Current perspectives in dissolution testing of conventional and novel dosage forms.Int. J. Pharm.20073281122110.1016/j.ijpharm.2006.10.001 17084051
     [Google Scholar]
  10. BharatJ. Badri PrakashN. SourabhJ. VipulV. RP-HPLC method for estimation of Dapoxetine HCl and Tadalafil HCl as API and in tablet dosage form.American J. Pharm. Tech. Res.20133757768
     [Google Scholar]
  11. KannapanN. DeepthiV. DivyaV. Method development and validation of stability indicating method for assay of Tadalafil and Sildenafil Citrate by HPLC.Int. J. Chemtech Res.20102329333
     [Google Scholar]
  12. KavithaA. VijayaD.D. HimaB.S. EshvendarK. KhaleelN. PaniK.D. Forced degradation studies, quantification and in-vitro dissolution studies of tadalafil by spectrofluorimetry.Asian J. Pharm. Clin. Res.20136326329
     [Google Scholar]
  13. MohammadY. GowriD.D. PragatiK.B. ShahulH. UV spectrophotometric method for the estimation of tadalafil in bulk and tablet dosage form.E-J. Chem.2010783383610.1155/2010/630576
     [Google Scholar]
  14. SafwanF. Spectrophotometric methods for the determination of tadalafil in pharmaceutical forms.Int. J. Pharm. Pharm. Sci.20146443445
     [Google Scholar]
  15. SankarM. ArulantonyS. A stability indicating RP-HPLC method for the estimation of tadalafil in oral jelly dosage forms.Indian J. Res.201321922
     [Google Scholar]
  16. SonawaneP.H. PanzadeP.S. KaleM.A. Rapid estimation of tadalafil by reverse phase high performance liquid chromatography.Indian J. Pharm. Sci.2013752230233 24019575
     [Google Scholar]
  17. PranjaliS.S. VaishnaviS.W. PratikS.K. JunedK.B. MadhukarA. RajeswariR.K. Method development and validation of HPLC as per ICH guidelines-A review.Int. J. Pharma Res.2024132916
     [Google Scholar]
  18. AkashD. RajmaneK.P. A review of HPLC method development and validation as per ICH guidelines.Asian J. Pharmac Anal.20231321431
     [Google Scholar]
  19. BarotT.G. PatelP.K. Determination of tadalafil in pure powder and tablet dosage form by high-performance liquid chromatography.J. AOAC Int.201093251652210.1093/jaoac/93.2.516 20480898
     [Google Scholar]
  20. BojanapuA. SubramaniamA.T. MunusamyJ. DhanapalK. ChennakesavaluJ. SellappanM. JayaprakashV. Validation and method development of tadalafil in bulk and tablet dosage form by RP-HPLC.Drug Res.2015652828510.1055/s‑0034‑1372608 24782284
     [Google Scholar]
  21. VyasA.J. GolD.A. PatelA.I. PatelA.B. PatelN.K. ChavdaJ.R. LumbhaniA. ChudasamaA. Implementing analytical quality by design (AQbD) approach for simultaneous estimation of tadalafil and macitentan by RP-HPLC method.Anal. Chem. Lett.202111453955210.1080/22297928.2021.1938215
     [Google Scholar]
  22. GolD. VyasA. VisanaN. PatelA. ShahS. ShethD. DholakiaS. Stability indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension.Ann. Pharm. Fr.202482346447210.1016/j.pharma.2023.10.006 37866638
     [Google Scholar]
/content/journals/csch/10.2174/0129504910393905250929062420
Loading
Validated RP-HPLC Method for Simultaneous Estimation of Tadalafil and Macitentan in Bulk and Dosage Forms
Curr Spectrosc Chromatogr 11, E29504910393905 (2025); https://doi.org/10.2174/0129504910393905250929062420
/content/journals/csch/10.2174/0129504910393905250929062420
/content/journals/csch/10.2174/0129504910393905250929062420
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): High-performance liquid chromatography; limit of detection/limit of quantification; macitentan; phosphodiesterase type 5; pulmonary arterial hypertension; tadalafil
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test